Skip to main content

Drug Interactions between gemfibrozil and selexipag

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

gemfibrozil selexipag

Applies to: gemfibrozil and selexipag

CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 2C8 may significantly increase the plasma concentrations of selexipag and its active metabolite. In 20 healthy male subjects, treatment with the potent CYP450 2C8 inhibitor gemfibrozil (600 mg twice a day on days 1 to 9) in combination with selexipag (400 mcg once in the morning on day 4) resulted in a 1.4 and 2-fold increase in the Cmax and AUC of selexipag, respectively, and a 3.6 and 11.1-fold increase in the Cmax and AUC of its active metabolite, respectively.

MANAGEMENT: Concomitant use of selexipag with potent CYP450 2C8 inhibitors is contraindicated by the manufacturer.

References (4)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2016) "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc
  4. Bruderer S, Petersen-Sylla M, Boehler M, Remenova T, Halabi A, Dingemanse J (2017) "Effect of gemfibrozil or rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects." Br J Clin Pharmacol, epub

Drug and food interactions

Minor

selexipag food

Applies to: selexipag

Food prolongs the gastrointestinal absorption of selexipag. When taken with food, the time to peak concentration (Tmax) was delayed and peak plasma concentration (Cmax) was approximately 30% lower. Selexipag systemic exposure (AUC) and that of its active metabolite did not significantly change, however. Selexipag may be taken with or without food. Tolerability may be improved when taken with food.

References (1)
  1. (2016) "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer